Recent advances in genomics, transcriptomics, and proteomics have given us more insight into and understanding of cancer genetics. With this accumulation of knowledge, it has become apparent that cancer etiology is extremely complex and heterogeneous; even within a single organ such as breast, multiple subtypes of cancer have been identified. It is imperative that our therapeutic strategies address the complexity and heterogeneity within the disease. Rodent tumor models have been generated since the 1960s, with xenografted human tumor models emerging in the 1980s (reviewed in \[[@B1]\]). However, only recently have technological advances allowed comparison of xenografted tumors to primary patient tumors at a level previously unobtainable, allowing the subtype classification of patient-derived xenograft (PDX) tumors. Additionally, new technologies such as intravital microscopy show unique conserved morphology and vascularization compared to injected cell lines, thus allowing prediction and optimization of therapeutic strategies based on tumor biology.

Although breast cancer cell lines are informative and have been widely used due to their well-defined characteristics, they do not adequately reflect breast cancer heterogeneity or morphology *in vivo*and are poorly metastatic from the orthotopic site, thus limiting their predictive value in the clinical setting \[[@B2]-[@B4]\]. In contrast, PDXs retain morphology, cellular heterogeneity, and molecular profiles of the original patient tumors \[[@B1],[@B4]-[@B9]\]. Currently, xenografts from patient derived-tumors have proven to be an effective model for screening potential chemotherapeutics and translating to efficacy in clinical trials \[[@B2],[@B5],[@B10],[@B11]\]. To evaluate the efficacy of potential therapeutics, PDXs provide the ability to place the same \'patient\' on all arms of a trial in preclinical studies. The key to successfully identifying novel cancer therapies will be selecting representative models, recognizing limitations of each model, and evaluating the correct endpoints that reflect therapeutic efficacy. With recent efforts to fully characterize unique PDX lines by molecular subtyping and mutation analysis, we are well poised to initiate studies that can identify subsets of patients that will potentially respond to novel cancer therapies, thus bringing us several steps closer to personalized medicine.

Recent advances in patient-derived xenograft models
===================================================

The proven predictive ability and translation of cancer therapies from PDX tumor models has led to a renewed interest in developing PDX models \[[@B2],[@B5],[@B10]-[@B12]\]. Previous improvements in engraftment approaches, including orthotopic transplantation into the mammary fat pad, co-injection of basal membrane extract, and utilization of more severely immunocompromised mouse models, set the stage for advances in generating PDX cohorts from human breast tumors \[[@B13]-[@B16]\]. Several groups, including ours, have generated stable cohorts of breast cancer PDXs (Table [1](#T1){ref-type="table"}) \[[@B1],[@B6],[@B8],[@B9],[@B11],[@B17]-[@B22]\]. For this review, we will focus on academic, rather than commercial, stable breast tumor PDX cohorts.

###### 

Generation of breast tumor patient-derived xenografts

                                                       **Visonneau *et al*.**\[[@B1]\]                                                     **Al Hajj *et al*.**\[[@B17]\]**; Liu *et al*.**\[[@B19]\]            **Beckhove *et al*.**\[[@B18]\]                                                            **Marangoni *et al*.**\[[@B6]\]**; Cottu *et al*.**\[[@B21]\]**; Reyal *et al*.**\[[@B23]\]   **Bergamaschi *et al*.**\[[@B24]\]                                        **DeRose *et al*.**\[[@B8]\]                                      **Zhang *et al*.**\[[@B9]\]                       **Kabos *et al*.**\[[@B20]\]                                                **Petrillo *et al*.**\[[@B22]\]
  ---------------------------------------------------- ----------------------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------
  Transplantation site                                 Subcutaneous                                                                        Orthotopic, thoracic mammary gland                                    Intramuscular hind leg, matrigel                                                           Interscapular fatpad                                                                          Subcutaneous back pocket, matrigel                                        Orthotopic, cleared mammary fatpad                                Orthotopic, cleared mammary fatpad                Orthotopic, abdominal fatpad, matrigel                                      Subcutaneous dorsal flank
  Additional immunosuppression                         Etoposide                                                                           Etoposide                                                             Irradiated versus non-irradiated                                                           None                                                                                          None                                                                      None                                                              None                                              None                                                                        None
  Estradiol                                            None                                                                                Yes, 5 days before transplant                                         None                                                                                       In drinking water 17 μg/ml \[[@B6]\]; 8 μg/ml \[[@B21]\]                                      1.7 mg/pellet; 900 pg/ml                                                  Yes                                                               Yes, low dose                                     Yes, silastic pellet                                                        Yes, 0.36 mg pellet
  Mouse strain                                         SCID                                                                                NOD/SCID, NSG                                                         NOD/SCID                                                                                   Swiss nude                                                                                    SCID                                                                      NOD/SCID                                                          SCID/Beige, NSG                                   NOD/SCID, NSG                                                               NOD/SCID
  Initial take rate                                    Primary tumors 8/16 (50%)                                                                                                                                 93 versus 90% irradiated; versus non-irradiated                                            Primary (15%) \[[@B6]\] Metastasis (24%) \[[@B6]\]                                            6/30 (20%), TG2                                                           18/49 (37%)                                                                                                         10/24 (42%) \>TG1                                                           
  Stable take rate                                     Two lines were serially passaged                                                                                                                          Not serially passaged                                                                      12.5% total (25/200) \[[@B6]\]; 2.5% (8/213) luminal 25% non-luminal, TG3 \[[@B21]\]          3/30 (10%), TG8 2/30 (7%) \>TG10                                          12/49 (27%)                                                       27 lines representing individual patients \>TG5                                                                               5/20 (25%)
  Xenograft versus patient concordant histopathology   Yes, one exception                                                                                                                                        Yes                                                                                        Yes                                                                                           Yes                                                                       Yes                                                               Yes                                               Yes                                                                         Yes
  Engraftment correlation with tumor features          Take rate did not correlate with pathological diagnosis, grading, or ER/PR status   8/9 pleural effusions \[[@B17]\]; primary and metastases \[[@B19]\]   Progression correlated with negative hormone status, high proliferative index, grade III   TNBC and metastases higher; non-luminal higher take rate than luminal                         Not statistical but two stable were invasive grade III ductal carcinoma   8/12 stable grafts from metastatic pleural effusions or ascites   TNBC and grade III higher take rate               Non-luminal higher take rate than luminal; ER status and high tumor grade   Receptor subtype and pathological grade higher take rate
  IHC subtypes represented                                                                                                                 4 TN 2 HER2+ 2 ER+                                                                                                                                               15 TN 2 HER2+ 1 ER+ \[[@B6]\]; 22 TN, 8 ER+ \[[@B21]\]                                        1 ER-/PR- (lost PR) 1 ER+/PR+                                             5 TN 2 HER2+ 2 ER+ -                                              21 TN 3 HER2+ 3 ER+                               1 TN 5 ER+                                                                  0/12 ER/PR+ 4/4 TN 1/4 HER2+
  Metastases                                                                                                                               Yes, 5/8 (62%) micro-metastases \[[@B19]\]                            Rare, two in lymph nodes                                                                   10 models lung metastases                                                                                                                                               9/10 (90%)                                                        13/27 (48%) micro-metastases                                                                                                  
  Genetic stability across generations                                                                                                                                                                                                                                                                      Yes, CGH and Affymetrix microarray                                                                                                                                      Yes, Agilent and SNP microarray                                   Yes, genomic, transciptomic, proteomic                                                                                        

CGH, comparative genomic hybridization; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IHC, immunohistochemistry; NOD, non-obese diabetic; NSG, NOD/SCID/IL2γ-receptor null; PR, progesterone receptor; SCID, severe combined immunodeficiency; TG, transplant generation; TN, triple negative; TNBC, triple negative breast cancer.

Initially, additional immunosuppression by pretreatment with etoposide or irradiation was used to prevent host-graft rejection. Although breast tumor xenografts had proven to be quite challenging, Visonneau and colleagues \[[@B1]\] transplanted 16 patient biopsies subcutaneously into etoposide-pretreated severe combined immunodeficiency (SCID) mice, achieving a 50% take rate with systemic spread and serial passage of two lines. In addition, they reported that transplantation of an aggressive metastatic xenograft into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice reduced metastasis, and soluble IL-2 receptor levels in the serum had a strong correlation with tumor load. Using a similar engraftment approach, Al Hajj and colleagues \[[@B17]\] transplanted patient tumors into the thoracic mammary gland fat pad of etoposide- and estrogen-pretreated NOD/SCID mice, thereby identifying a tumorigenic subpopulation of breast cancer cells. Notably, eight of these nine xenografts were derived from pleural effusions (PEs), indicating high take rate from metastatic sites. More recently, they generated additional models from primary tumors and metastatic sites, with the majority of these PDXs generating lung micrometastases \[[@B19]\]. Beckhove and colleagues \[[@B18]\] found that sub-lethal irradiation (3.75 Gy) to further suppress the immune system increased NOD/SCID mouse mortality compared to non-irradiated mice, without improving the engraftment rate or tumor marker expression of intramuscularly implanted tumor tissue (Table [1](#T1){ref-type="table"}; 93 versus 90% take rate, respectively). Both methods retained cytokeratin expression and induced host stromal cytokine expression similar to the original patient tumors, yet the non-irradiated hosts had more leukocyte infiltration into the tumors, leading to the conclusion that additional immunosuppression is not necessary for engraftment and may reduce important microenvironmental interactions.

Several groups have since reported successful engraftment without further immune suppression (Table [1](#T1){ref-type="table"}). By subcutaneously transplanting into the subscapular fatpad of estrogen-treated Swiss nude mice, Marangoni and colleagues \[[@B6]\] achieved a 15% and 24% initial engraftment rate from primary tumors and metastatic sites, respectively. These Swiss nude mouse models produced a 12.5% stable take rate (25/200) and ten models with lung metastases. In comparing xenograft response to patient response to treatment, a 5/7 concordance was observed, supporting the utility of these models for evaluating therapeutics. This French group has continued to lead efforts in PDXs, generating the first panel of luminal breast cancer xenografts and extensive molecular profiling of PDXs \[[@B21],[@B23]\]. These luminal models recapitulated heterogeneous clinical behaviors with varying sensitivities to hormone therapies \[[@B21]\]. Bergamaschi and colleagues \[[@B24]\] replaced Swiss nude mice with SCID mice to achieve a 20% initial take rate and establish two stable lines (7% stable take rate). Estrogen supplementation and transplantation into the interscapular fatpad have proven to be effective approaches to establishing PDXs.

Other groups have successfully employed orthotopic transplantation into the cleared mammary gland fat pad of SCID mice without additional immunosuppression (Table [1](#T1){ref-type="table"}). DeRose and colleagues had an initial engraftment rate of 37% and a stable take rate of 24% from 4 primary tumors, 7 pleural effusates, and 1 ascites \[[@B8]\]. The majority of these tumor grafts developed metastases with frequencies from 38% to 100% in sites corresponding to patient metastatic sites, recapitulating the original patient metastatic cascade. They also showed that implantation of human mesenchymal stem cells with tumors improved tumor growth and stability by enhancing tumor vascularization and preserved estrogen receptor (ER) expression. Zhang and colleagues \[[@B9]\] established a large cohort of 35 stable lines representing 27 independent patients, with 12 lines (48%) developing metastatic lesions in the lungs. Low dose estrogen supplementation without exogenous human fibroblasts proved to be the most conducive condition for establishing PDXs. Kabos and colleagues \[[@B20]\] developed five stable luminal PDXs that retained hormone receptor expression after serial transplantation and reflected clinical heterogeneity with estrogen-dependent gene signatures. Interestingly, estrogen supplementation has improved take rate and enhanced tumor growth regardless of hormone receptor status in the tumor cells \[[@B25]-[@B27]\]. This may be explained by a recent report suggesting estrogen stimulation of ER-negative tumor growth is, in part, due to ERα-mediated effects on bone marrow-derived myeloid cells that promote angiogenesis and tumor growth \[[@B27]\].

The various SCID models (SCID, SCID/Beige, NOD/SCID/IL2γ-receptor null (NSG)) have been equally successful \[[@B1],[@B6],[@B8],[@B9],[@B17],[@B19]\], but the nude (nu) mutation or combined bg/nu/xid mutation mice had been relatively resistant to initial engraftment of human breast tumors \[[@B1]\] until Marangoni and colleagues \[[@B6]\] achieved success with Swiss nude mice. In general, SCID models are more permissive to systemic spread (Table [1](#T1){ref-type="table"}) \[[@B8],[@B9],[@B19]\]. This is likely due to the increased severity and stability of immunodepletion in the SCID models compared to the nude mice. Whereas initial reports found no correlation between engraftment and pathological diagnosis, grading, or ER/progesterone receptor (PR) status \[[@B1]\], several groups since have found that take rate correlates with tumor grade, with the most aggressive grade III and IV triple negative breast cancers (TNBCs) having higher take rates than ER+ tumors (Table [1](#T1){ref-type="table"}) \[[@B6],[@B9],[@B18],[@B21],[@B22],[@B24]\]. Accordingly, the cohorts of PDXs have been inherently biased towards TNBC until recent efforts focused on generating luminal cohorts \[[@B20],[@B21]\]. Moreover, metastatic lesions generally have higher take rates than primary tumors \[[@B6],[@B8]\].

Regardless of the challenges in establishing PDX, these models generally retain the pathological characteristics and biomarker status of the original patient tumor and have proven to be stable across multiple transplant generations. Several groups have documented retention of histopathological characteristics and biomarker status by evaluating original patient tumors and corresponding PDXs in subsequent generations by standard hematoxylin and eosin staining and immunohistochemistry (IHC) techniques for ER, PR, human epidermal growth factor receptor-2 (HER2), and proliferative index (Ki67) (Table [1](#T1){ref-type="table"}) \[[@B1],[@B8],[@B9],[@B18]-[@B23]\]. Genomic analysis by paired-end sequencing, comparative genomic hybridization, and SNP as well as transciptomic evaluation by Affymetrix and Agilent gene expression analysis show shared alterations between primary and xenograft tumors, with more pronounced mutational status or aggressiveness tumor characteristics in PDXs (Table [2](#T2){ref-type="table"}) \[[@B7],[@B8],[@B21]-[@B24]\]. By comparing deep sequencing results of a basal-like TN patient breast tumor, blood, metastasis and PDX, Ding and colleagues \[[@B7]\] found that the PDX retained the mutations of the primary tumor and gained additional mutations comparable to the patient metastasis. In another example, genomic analysis of one patient tumor had one wild-type TP53 allele with the corresponding xenograft having loss-of-heterozygosity in TP53, and an ER+ tumor gained basal-like alterations \[[@B24]\]. Reyal and colleagues \[[@B23]\] reported less than 5% of genes had recurrent variation between patient tumors and xenografts; not surprisingly, these genes corresponded to human stromal compartment genes. In summary, these highly characterized PDX models serve as a renewable resource of human breast tumor tissue and preclinical models for preclinical evaluation of novel cancer therapies.

###### 

Genomic and transcriptomic evaluation of breast tumor patient-derived xenografts

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   **Marangoni *et al*.**\[[@B6]\]**; Cottu *et al*.**\[[@B21]\]**; Reyal *et al*.**\[[@B23]\]                                                                                                                                                                                                                           **Bergamaschi *et al*.**\[[@B24]\]                                                                                                                                                                                                                                                       **Ding *et al*.**\[[@B7]\]                                                                                                                                     **DeRose *et al*.**\[[@B8]\]                                        **Kabos *et al*.**\[[@B20]\]                          **Petrillo *et al*.**\[[@B22]\]
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  Genomic                          DNA copy number alterations: 14/18 pairs of tumors shared more than 56% copy number alterations, unsupervised hierarchical clustering showed 16/18 pairs segregated together. Recurrent changes between patient tumors and xenografts showed losses in 176 chromosomal regions and gains in 202 chromosomal regions   CGH array Agilent 244K human genome CGH microarrays. CGH results showed shared alterations between primary and xenograft tumors with more pronounced alterations in engrafted tumors, that is, TP53 patient 1 wild-type allele, xenograft LOH; ER+ tumor gained basal-like alterations   Paired-end sequencing to achieve deep coverage of patient blood, tumor, metastasis, and xenografted tumor Confirmed SNP coverage by Illumina 1M duo arrays.\   Genome-wide SNPs with enhancement of existing aberrations                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The PDX retained primary tumor mutations and showed enrichment of mutations similar to patient metastasis                                                                                                                                                                                

  Microarray-gene expression       Gene expression analysis (GEA)                                                                                                                                                                                                                                                                                        Agilent GEA High dose E2 supplementation altered gene expression                                                                                                                                                                                                                         PAM50 intrinsic subtype classification                                                                                                                         Agilent GEA, intrinsic subtype classification, PAM50 confirmation   Agilent GEA, PAM50 intrinsic subtype classification   Agilent GEA, PAM50 intrinsic subtype classification

  Intrinsic subtypes represented   Basal-like (5)\                                                                                                                                                                                                                                                                                                       Basal-like (1)\                                                                                                                                                                                                                                                                          Basal-like (1)                                                                                                                                                 Basal-like (4)\                                                     Basal-like (1)\                                       Basal-like (3)\
                                   Luminal A (2)\                                                                                                                                                                                                                                                                                                        Luminal B (1)                                                                                                                                                                                                                                                                                                                                                                                                                                           HER2-like (1)\                                                      HER2-like (1)\                                        Luminal A (1)
                                   Luminal B (1) \[[@B23]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Luminal B (4)\                                                      Luminal B (4)                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Normal-like (1)                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CGH, comparative genomic hybridization; ER, estrogen receptor; GEA, gene expression analysis; HER2, human epidermal growth factor receptor-2; LOH, loss of heterozygosity; PDX, patient-derived xenograft.

Therapeutic application of breast tumor patient-derived xenografts
==================================================================

Although breast cancer cell lines are widely used for mechanistic and therapeutic studies due to their well-defined characteristics, they do not adequately reflect breast cancer heterogeneity or morphology *in vivo*, thus limiting their predictive value. Furthermore, most breast cancer cell lines when orthotopically injected do not efficiently metastasize and require tail vein injection to generate contrived metastatic models. In contrast, PDXs retain the morphology, cellular heterogeneity, and molecular profiles of the original patient tumors \[[@B1],[@B4]-[@B9],[@B20]-[@B22]\], thereby being relevant preclinical models to identify effective therapeutic regimens that can be translated into clinical practice. PDXs recapitulate the heterogeneity of treatment response as seen in the clinic and show concordance with the original patient\'s treatment response \[[@B6],[@B20],[@B21]\]. Additionally, the orthotopic transplant models have proven to efficiently recapitulate human metastatic lesions and sites (Table [1](#T1){ref-type="table"}). Translating preclinical data to the clinic requires appropriate selection of representative models, recognition of intrinsic limitations for each model, and selection of the appropriate endpoints to identify effective therapeutic regimens.

While the applications and utility of PDXs are enormous, it is important to recognize the limitations of these PDXs in interpreting results. The two fundamental limitations of PDXs are the mouse microenvironment and the lack of an intact immune system. In contrast to human breast epithelium that is surrounded by intra- and inter-lobular stroma and has minimal contact with adipose tissue, mouse breast epithelium is embedded mostly in adipose tissue with interspersed connective tissue \[[@B28]\]. In the PDX models, stromal components within the tumor are actually better than expected; the tumor epithelium is able to effectively communicate with the mouse stroma to recapitulate the histopathogical characteristics of the patient original tumor. Mouse connective tissue and other stromal components are interspersed in the tumor epithelium \[[@B8],[@B23]\]. That being said, it is uncertain how closely the mouse and human cell interactions resemble that of the human stroma/human tumor, and exactly what components are missing. Several successful efforts to recapitulate human breast stroma in mice have been reported \[[@B29],[@B30]\]. It has been shown that normal fibroblasts can inhibit transformed mammary epithelial cell growth \[[@B31]\]; therefore, it will be critical to properly match tumor-associated stroma. In our hands, implanting irradiated human fibroblasts actually reduced stable take rate of human breast tumors. Although generating PDXs with humanized stroma components can improve the evaluation of microenvironmental influences on treatment response for a limited number of models \[[@B32]\], technical challenges of matching each tumor with its own stromal components currently precludes generation of large cohorts for preclinical testing.

Additionally, these models lack an intact immune system, which can play both a prohibitive and activating role in tumor development and therapeutic response (reviewed in \[[@B33]\]). Well-defined genetically engineered mouse models that represent the heterogeneity and complexity of tumor etiology, such as TP53 null tumor models, will be essential in evaluating immunological effects on tumor development and therapeutic response \[[@B34]\]. Additional efforts are ongoing to humanize the immune system in mice \[[@B35],[@B36]\]; however, to prevent rejection of xenografts, the humanized immune cells have to precisely match the tumor, thus restricting large cohort development currently.

Finally, identification of novel therapeutics in preclinical models requires appropriate end point evaluation. Recent ARRIVE (Animals in Research: Reporting *In Vivo*Experiments) guidelines provide a thorough checklist of 20 items, from experimental design to statistical analysis, that should be included to improve the quality of reports and interpretation of results from animal studies \[[@B37]\]. In considering study endpoints to be evaluated, generally tumor volume and toxicity measurements are standard methods of monitoring treatment effects. Tumor growth rate should be considered for determining treatment duration in detecting a significant response in tumor growth. Based on therapy resistance and increasing evidence supporting the cancer stem cell (CSC) hypothesis \[[@B38]-[@B40]\], tumor recurrence after treatment cessation and functional CSC assays can also be critical endpoints in evaluating treatment response to targeted therapies. Recurrence studies replicate the clinical setting with multiple treatment cycles \[[@B3]-[@B6]\], while monitoring body weight and tumor volume to report time to elimination of tumors and time to recurrence after cessation of treatment.

According to the CSC hypothesis, tumor cells exist in a hierarchy with a select population, that is, CSCs or tumor-initiating cells, being responsible for initiation and recurrence of tumors. To monitor effects on CSCs, tumors are collected for downstream CSC assays, including mammosphere formation efficiency, flow cytometric analysis of CSC markers, and limiting dilution retransplantation of treated tumor cells. Recent reports have evaluated one to three PDX lines and complemented with two to three cell line xenografts to evaluate potential cancer therapies, and define mechanisms underlying treatment response or resistance \[[@B41]-[@B43]\]. This is due, in part, to the inherent challenges of isolating viable cells after dissociation of solid tumors for downstream assays. Additionally, the labor involved and financial considerations are likely to limit the number of lines evaluated in this manner.

Not all tumor lines retain viability and functional capacity after dissociation, with the more aggressive metastasis-derived lines being more amenable to manipulations. Recently, we overcame the challenge of limited cell viability inherent in dissociation of solid tumors by transplanting equal size, intact fragments (10 mg containing 1 × 10^5^cells) and monitoring tumor initiation with or without targeted treatment to successfully detect inhibition of tumor initiation with treatment. Efforts are still underway to improve isolation of single cell suspensions so that all tumor lines can be evaluated by downstream functional assays such as CSC assays, epithelial-to-mesenchymal transition assays, and flow cytometric measurement of signaling pathways within different cell types.

Since the availability of PDX lines has expanded and these tumors have been fully characterized by the efforts of multiple groups, it is now possible to carry out preclinical clinical trials in which a panel of tumors representing individual patients is assigned to each arm of a study for direct comparison of treatment strategies. Moreover, with molecular profiling, treatment response can be evaluated according to subtype classification.

Molecular subtyping of breast tumor patient-derived xenografts
==============================================================

Molecular profiling has identified at least six intrinsic breast cancer subtypes (luminal A, luminal B, HER2-enriched, basal-like, claudin-low, and a normal-like group) with clinically significant differences in risk factors, incidence, and baseline prognosis, and treatment response \[[@B44]-[@B49]\]. Molecular subtypes more accurately predict clinical response than standard pathological staging and immunohistochemical classification of tumors by ER, PR, HER2, and Ki67 expression \[[@B47],[@B50],[@B51]\]. To determine the intrinsic tumor subtypes of breast tumor PDX, the Welm group carried out global gene expression microarray analysis and then performed hierarchical clustering with the UNC337 human dataset that represents the intrinsic molecular subtypes \[[@B47],[@B49]\]. Similar classifications were shown using the PAM50 supervised subtype predictor \[[@B47],[@B48]\]. Breast tumor PDX clustered within the intrinsic subtypes of breast cancer rather than forming a separate cluster (Table [2](#T2){ref-type="table"}) \[[@B8],[@B22],[@B23]\]. Furthermore, these PDX models displayed genetic stability, as original human tumors and multiple generations of xenografts clustered together, reflecting shared gene expression between PDXs and patient tumors \[[@B8],[@B22],[@B23]\]. Not all intrinsic breast tumor subtypes are equally represented by the current PDX lines, with a bias toward the basal-like subtype (Table [2](#T2){ref-type="table"}). This is due to increased engraftment rate from late stage and metastatic tumors, which tend to be TN and HER2+ (Table [1](#T1){ref-type="table"}). Luminal tumors, which inherently have lower pathological grades and slower growth rates, have historically been difficult to establish. Although the take rates of ER+ tumors are much lower compared to TN (2.5% versus 25% \[[@B21]\]), recent efforts focusing on generation of luminal tumors has increased the number of stable luminal PDXs \[[@B20],[@B21]\]. DeRose and colleagues \[[@B8]\] established four luminal B PDXs with human mesenchymal stem cell cotransplantation. Despite these efforts, luminal A tumors still have limited numbers amongst the established PDX lines (Table [2](#T2){ref-type="table"}). As PDX model development continues, the representation of each of the intrinsic breast tumor subtypes should become more comprehensive.

TNBC describes not a single tumor type but a diverse group of cancers requiring distinct targeted therapies. Lehmann and colleagues \[[@B52]\] identified six unique TNBC subtypes with unique molecular profiles and ontologies that can inform therapy selection in TNBC, including: basal-like 1 and 2 (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem cell-like (MSL), and luminal androgen receptor (LAR). We used their methods to determine the subtype of 15 TNBC PDXs: most (8 of 15) classified as BL1 (Table [3](#T3){ref-type="table"}; unpublished observations). While the most frequently occurring subtypes (BL1 = 8, M = 3 and BL2/IM = 1) were identified in our PDX models of TNBC, it is only a matter of time before it can be determined if all of the Pietenpol subtypes are represented in PDXs, as they have developed a user-friendly web-based application, \'TNBCtype\', in which researchers can classify their samples \[[@B53]\]. Altogether, Perou intrinsic subtype classification and Pietenpol TNBC classification of PDX cohorts has the potential to further classify PDXs, identify novel treatment regimens, and facilitate appropriate patient selection for clinical trials.

###### 

Pietenpol triple negative breast cancer subtype classification of patient-derived xenografts

       Patient-derived xenograft lines   Pietenpol triple negative breast cancer subtype
  ---- --------------------------------- -------------------------------------------------
  1    BCM-2147/2277                     BL1
  2    BCM-2665A                         BL1
  3    BCM-3611/3824                     BL1
  4    BCM-3904                          BL1
  5    BCM-4664                          BL1
  6    BCM-4913/5438                     BL1
  7    BCM-3936                          BL1/UNC
  8    BCM-4175                          M
  9    BCM-4272/4849                     UNC/BL1
  10   BCM-3807/4400                     IM/BL2
  11   BCM-3107                          M
  12   BCM-3204                          M
  13   BCM-3887                          UNC
  14   BCM-4013                          UNC
  15   BCM-3561                          UNC

Pietenpol classification \[[@B52],[@B53]\]: BL1, basal-like 1; BL2, basal-like 2; IM, immunomodulatory; M, mesenchymal-like; MSL, mesenchymal stem-like; UNC, unclassified.

Conclusion
==========

Personalized medicine is intended to select subsets of patients that will most likely respond to treatment regimens, thus reducing morbidity and mortality from ineffective treatments. To identify targeted therapies and effective treatment regimens based on subtype classification, representative breast tumor PDXs can be assigned to each arm of a preclinical clinical trial (Figure [1](#F1){ref-type="fig"}). Integration of *in vivo*models of PDXs, TP53 genetically engineered mouse tumor models, and representative cell line-derived xenograft tumors will allow representation of the full range of subtypes and tumor heterogeneity. Alternatively, preclinical clinical trials may focus on TNBC using the Pietenpol TNBC subtypes to identify the subtypes responsive to different treatment regimens. Based on the complexity of signaling pathways driving tumorigenesis and/or metastasis, cocktails of inhibitors will ultimately be required to prevent recurrence and treatment resistance. In the near future, the knowledge gained by the ongoing efforts of genomic classification from complete genome sequencing of patient tumors and PDX is expected to drive the next generation of preclinical clinical trials aimed at personalizing cancer therapy.

![**Schematic of preclinical clinical trials: from classification to patient selection for clinical trials**. Based on the advances in generating patient-derived xenografts and breast cancer subtyping, preclinical trials can be designed to provide subtype-specific outcome data and to identify molecular profiles of tumors that respond to specific therapies, thus having the potential to better guide patient selection for clinical trials and to reduce costs and ineffective treatment options for patients. Patient-derived xenografts are subtyped by standard immunohistochemistry (IHC) and by molecular profiling and then placed on each arm of a preclinical clinical trial for direct comparison of treatment strategies. The treatment response is then correlated with subtype classification to identify the responsive versus non-responsive tumor subtypes that correspond to patient tumor subtypes to guide selection for clinical trials.](bcr3355-1){#F1}
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